Merck & Co. (MRK) Releases Earnings Results, Beats Expectations By $0.04 EPS

Merck & Co. (MRK) reported quarterly earnings results on Thursday, May-5-2016. The company said it had a profit of $0.89 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.04. Analysts had a consensus of $0.85. The company posted revenue of $9312.00 million in the period, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.85 EPS.

Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.

Merck & Co. closed down -0.27 points or -0.49% at $54.81 with 77,05,950 shares getting traded on Wednesday. Post opening the session at $54.71, the shares hit an intraday low of $54.4662 and an intraday high of $55.04 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

In a different news, on Apr 14, 2016, Kenneth C Frazier (Chairman, President & CEO) sold 131,040 shares at $56.11 per share price. According to the SEC, on Nov 4, 2015, Wendell P Weeks (director) sold 5,000 shares at $55.53 per share price. On Oct 29, 2015, Adele D Ambrose (Sr.V-P & Chief Comuns Officer) sold 37,313 shares at $55.08 per share price, according to the Form-4 filing with the securities and exchange commission.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Merck & Co.

Leave a Reply

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.